🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsSemaglutide (Ozempic / Wegovy)STEP 1-5 trials comprehensive summary — my results so far Page 3

STEP 1-5 trials comprehensive summary — my results so far

ben_calgary Wed, Apr 16, 2025 at 10:35 AM 40 replies 2,086 viewsPage 3 of 8
hank_denver
Member
278
1,234
Sep 2024
Denver, CO
Apr 22, 2025 at 2:44 PM#11
lisa_labSD said:
Albumin binding above 99% is the whole reason weekly dosing works, and it is also why the trough matters more than the peak.

Saving this. It is the first explanation that did not require me to already understand it.

14 12ingrid_STO, pete_nash, hank_denver and 11 others
Reply Quote Save Share Report
lisa_labSD
Member
278
1,234
Oct 2024
San Diego, CA
Apr 23, 2025 at 5:35 AM#12

Clinical perspective, offered as context rather than as advice.

ben_calgary said:
...but the FDA says semaglutide...

Interesting point. I want to add some regulatory nuance: the FDA labeling reflects the specific clinical trial data submitted for approval. Real-world clinical practice often extends beyond the FDA label based on emerging evidence and clinical judgment.

Example: semaglutide was first approved for diabetes (Ozempic), then obesity (Wegovy). The molecule didn't change — our understanding of its applications expanded. Similarly, semaglutide may evolve as more data accumulates.

15 13maya_sedona, stefan_berlin, Dr.EM_Chicago and 12 others
Reply Quote Save Share Report
LipidDoc_ATL
Senior Member
1,123
5,678
Apr 2024
Atlanta, GA
Apr 23, 2025 at 8:26 PM#13
SarahChen_PharmD said:
The dose-response is real but shallow at the top.

I will push back on the "any working dose is fine" framing. The maintenance evidence sits overwhelmingly at the top studied dose, and the extension data shows regain tracking dose reduction rather than tracking stopping. Holding low is reasonable; pretending it is evidentially equivalent is not.

16 14AttorneyGrant, DebRD_ATL, KristenIndy and 13 others
Reply Quote Save Share Report

Janoshik Analytical — Independent Testing

Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.

Verify Your Peptides

GL Biochem (Shanghai) Ltd. — Direct Manufacturer

Est. 1998. The synthesis house behind the vials you send for testing. ISO 9001 and cGMP certified, 1,500+ staff, batch-specific COA with every order.

Browse GL Biochem
SleepDoc_PDX
Member
289
1,234
Sep 2024
Portland, OR
Apr 24, 2025 at 11:17 AM#14

The figures, for anyone assembling their own picture. A quick sanity check on any figure quoted here: is it mean or median, is it intention-to-treat or completers, and what was the comparator. Three questions, and they resolve most disagreements in these threads.

Worth separating that from the trial evidence, which this thread keeps folding into the same question. They behave differently and the advice does not transfer.

Correct me if the detail matters more than I have assumed.

17 15sophie_paris, mel_PDX, Dr.AddMedPHL and 14 others
Reply Quote Save Share Report
Admin
Administrator
2,456
9,812
Oct 2023
Online
Apr 25, 2025 at 2:07 AM#15

Moderator note: two posts asking for a source have been merged into one. Please search the thread before asking again. Report rather than reply if it drifts again.

18 16PeptideSynthNJ, Dr.KarenChen, Dr.NateNeph and 15 others
Reply Quote Save Share Report

Similar Threads

STEP 1-5 trials comprehensive summary — efficacy endpoints compiled12 replies
Oral semaglutide 50mg Phase 3 — OASIS program results16 replies
Semaglutide pharmacokinetics — half-life, Tmax, steady state modeling10 replies
Compounded semaglutide stability data — temperature and light sensitivity16 replies
0.25mg → 2.4mg titration: optimal schedule based on clinical data6 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register